FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914079964> ?p ?o ?g. }

• W2914079964 endingPage "274" @default.
• W2914079964 startingPage "265" @default.
• W2914079964 abstract "Background Cadazolid is a novel quinoxolidinone antibiotic developed for treating Clostridium difficile infection. We aimed to investigate the safety and efficacy of cadazolid compared with vancomycin in patients with C difficile infection. Methods IMPACT 1 and IMPACT 2 were identically designed, multicentre, double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. IMPACT 1 was done in Australia, Brazil, Canada, France, Germany, Italy, the Netherlands, Peru, Poland, Romania, Spain, and the USA, and IMPACT 2 was done in Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czech Republic, Greece, Hungary, Israel, Romania, Slovakia, South Korea, the UK, and the USA. Patients (aged 18 years or older) with mild-to-moderate or severe C difficile infection (diarrhoea with positive glutamate dehydrogenase and toxin A or B enzyme immunoassays) were randomly assigned (1:1) with a randomisation list stratified by centre and C difficile infection episode type (block size of four), and allocation was masked to investigators and participants. Patients received either oral cadazolid 250 mg twice daily with vancomycin-matching placebo capsule four times daily or oral vancomycin 125 mg four times a day with cadazolid-matching placebo suspension twice daily for 10 days, with 30 days of follow-up. The primary efficacy outcome was non-inferiority (margin −10%) of cadazolid versus vancomycin for clinical cure in the modified intention-to-treat and per-protocol populations. Clinical cure was defined as resolution of diarrhoea with no additional treatment for C difficile infection. These trials are registered with ClinicalTrials.gov, numbers NCT01987895 (IMPACT 1) and NCT01983683 (IMPACT 2). Findings Between March 28, 2014, and March 24, 2017, for IMPACT 1, and Dec 13, 2013, and May 2, 2017, for IMPACT 2, 1263 participants were randomly assigned to receive cadazolid (306 in IMPACT 1 and 298 in IMPACT 2) or vancomycin (326 in IMPACT 1 and 311 in IMPACT 2). In the modified intention-to-treat population in IMPACT 1, 253 (84%) of 302 had clinical cure in the cadazolid group versus 271 (85%) of 318 in the vancomycin group. In IMPACT 2, 235 (81%) of 290 versus 258 (86%) of 301 had clinical cure. In the per-protocol population, 247 (88%) of 282 versus 264 (92%) of 288 had clinical cure in IMPACT 1 and 214 (87%) of 247 versus 237 (92%) of 259 in IMPACT 2. Non-inferiority for clinical cure to vancomycin was shown in IMPACT 1 but not in IMPACT 2 (IMPACT 1 treatment difference: −1·4 [95% CI −7·2 to 4·3] for modified intention to treat and −4·1 [–9·2 to 1·0] for per protocol; IMPACT 2: −4·7 [–10·7 to 1·3] for modified intention to treat and −4·9 [–10·4 to 0·6] for per protocol). The safety and tolerability profiles of the two antibiotics were similar. Interpretation Cadazolid was safe and well tolerated but did not achieve its primary endpoint of non-inferiority to vancomycin for clinical cure in one of two phase 3 C difficile infection trials. Therefore, further commercial development of cadazolid for C difficile infection is unlikely. Funding Actelion Pharmaceuticals." @default.
• W2914079964 created "2019-02-21" @default.
• W2914079964 creator A5002008542 @default.
• W2914079964 creator A5004530894 @default.
• W2914079964 creator A5024258790 @default.
• W2914079964 creator A5026731919 @default.
• W2914079964 creator A5027928189 @default.
• W2914079964 creator A5030279733 @default.
• W2914079964 creator A5032552975 @default.
• W2914079964 creator A5041580232 @default.
• W2914079964 creator A5043658814 @default.
• W2914079964 creator A5061487296 @default.
• W2914079964 creator A5063797660 @default.
• W2914079964 creator A5080609948 @default.
• W2914079964 creator A5082375532 @default.
• W2914079964 creator A5086890870 @default.
• W2914079964 date "2019-03-01" @default.
• W2914079964 modified "2023-10-16" @default.
• W2914079964 title "Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials" @default.
• W2914079964 cites W1559039796 @default.
• W2914079964 cites W1916481354 @default.
• W2914079964 cites W1977141047 @default.
• W2914079964 cites W2082889349 @default.
• W2914079964 cites W2098587497 @default.
• W2914079964 cites W2101294480 @default.
• W2914079964 cites W2106245002 @default.
• W2914079964 cites W2108693491 @default.
• W2914079964 cites W2113556993 @default.
• W2914079964 cites W2119031245 @default.
• W2914079964 cites W2131038214 @default.
• W2914079964 cites W2132537147 @default.
• W2914079964 cites W2148171446 @default.
• W2914079964 cites W2155106081 @default.
• W2914079964 cites W2165050668 @default.
• W2914079964 cites W2167805911 @default.
• W2914079964 cites W2512704070 @default.
• W2914079964 cites W2582069104 @default.
• W2914079964 cites W2588484778 @default.
• W2914079964 cites W2752378836 @default.
• W2914079964 cites W2767241397 @default.
• W2914079964 cites W2781567656 @default.
• W2914079964 cites W2791326569 @default.
• W2914079964 doi "https://doi.org/10.1016/s1473-3099(18)30614-5" @default.
• W2914079964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30709665" @default.
• W2914079964 hasPublicationYear "2019" @default.
• W2914079964 type Work @default.
• W2914079964 sameAs 2914079964 @default.
• W2914079964 citedByCount "37" @default.
• W2914079964 countsByYear W29140799642019 @default.
• W2914079964 countsByYear W29140799642020 @default.
• W2914079964 countsByYear W29140799642021 @default.
• W2914079964 countsByYear W29140799642022 @default.
• W2914079964 countsByYear W29140799642023 @default.
• W2914079964 crossrefType "journal-article" @default.
• W2914079964 hasAuthorship W2914079964A5002008542 @default.
• W2914079964 hasAuthorship W2914079964A5004530894 @default.
• W2914079964 hasAuthorship W2914079964A5024258790 @default.
• W2914079964 hasAuthorship W2914079964A5026731919 @default.
• W2914079964 hasAuthorship W2914079964A5027928189 @default.
• W2914079964 hasAuthorship W2914079964A5030279733 @default.
• W2914079964 hasAuthorship W2914079964A5032552975 @default.
• W2914079964 hasAuthorship W2914079964A5041580232 @default.
• W2914079964 hasAuthorship W2914079964A5043658814 @default.
• W2914079964 hasAuthorship W2914079964A5061487296 @default.
• W2914079964 hasAuthorship W2914079964A5063797660 @default.
• W2914079964 hasAuthorship W2914079964A5080609948 @default.
• W2914079964 hasAuthorship W2914079964A5082375532 @default.
• W2914079964 hasAuthorship W2914079964A5086890870 @default.
• W2914079964 hasBestOaLocation W29140799642 @default.
• W2914079964 hasConcept C126322002 @default.
• W2914079964 hasConcept C142724271 @default.
• W2914079964 hasConcept C204787440 @default.
• W2914079964 hasConcept C27081682 @default.
• W2914079964 hasConcept C2778980435 @default.
• W2914079964 hasConcept C2779489039 @default.
• W2914079964 hasConcept C2994496256 @default.
• W2914079964 hasConcept C501593827 @default.
• W2914079964 hasConcept C523546767 @default.
• W2914079964 hasConcept C535046627 @default.
• W2914079964 hasConcept C54355233 @default.
• W2914079964 hasConcept C71924100 @default.
• W2914079964 hasConcept C86803240 @default.
• W2914079964 hasConcept C89423630 @default.
• W2914079964 hasConceptScore W2914079964C126322002 @default.
• W2914079964 hasConceptScore W2914079964C142724271 @default.
• W2914079964 hasConceptScore W2914079964C204787440 @default.
• W2914079964 hasConceptScore W2914079964C27081682 @default.
• W2914079964 hasConceptScore W2914079964C2778980435 @default.
• W2914079964 hasConceptScore W2914079964C2779489039 @default.
• W2914079964 hasConceptScore W2914079964C2994496256 @default.
• W2914079964 hasConceptScore W2914079964C501593827 @default.
• W2914079964 hasConceptScore W2914079964C523546767 @default.
• W2914079964 hasConceptScore W2914079964C535046627 @default.
• W2914079964 hasConceptScore W2914079964C54355233 @default.
• W2914079964 hasConceptScore W2914079964C71924100 @default.
• W2914079964 hasConceptScore W2914079964C86803240 @default.
• W2914079964 hasConceptScore W2914079964C89423630 @default.
• W2914079964 hasFunder F4320338282 @default.

• next